### Summary of evidence and Expert Committee recommendations

The Committee recommended inclusion of tedizolid phosphate on the complementary list of the EML as a Reserve group antibiotic for the treatment of infections caused or suspected to be caused by multidrug-resistant Gram-positive pathogens (methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci), as an alternative to linezolid under a square box listing. The recommendation was based on evidence indicating that tedizolid is non-inferior to linezolid for the treatment of acute bacterial skin and skin structure infections, with a lower incidence of adverse events. However, the Committee observed that tedizolid phosphate is currently less widely available and considerably more expensive than linezolid. Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of linezolid 150 mg dispersible tablets to the EMLc, the removal of linezolid 400 mg tablets from the EML and EMLc, and the removal of linezolid 600 mg tablets from the EMLc.